HFS
XENE icon

Hantz Financial Services’s Xenon Pharmaceuticals XENE Stock Holding History

Hantz Financial Services’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
25
– – ﹤0.01% 2336
2026
Q1 		$1K Hold
25
– – ﹤0.01% 2411
2025
Q4 		$1K Buy
+25
New +$1.05K ﹤0.01% 2372

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hantz Financial Services's XENE Position: Q2 2026 in Review

Hantz Financial Services held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 25 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Hantz Financial Services first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Hantz Financial Services held 25 shares of Xenon Pharmaceuticals worth $2K as of Q2 2026.
  • Hantz Financial Services left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2336 holding.
  • Hantz Financial Services first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.